Nemes Laszlo/iStock via Getty Images Nkarta ( NASDAQ: NKTX ) is ending development of NKX019 in non-Hodgkin lymphoma. However, the candidate will continue to advance for autoimmune disease indications. The company said that the decision was made based on an assessment of the latest group of large B-cell.
